{
    "clinical_study": {
        "@rank": "149735", 
        "arm_group": {
            "arm_group_label": "Torrent's Olanzapine Orally Disintegrating Tablets 5mg", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Objective:\n\n      Primary objective of the present study was to compare the single dose bioavailability of\n      Torrent's Olanzapine Orally Disintegrating 5 mg Tablets versus Zyprexa\u00ae Zydis\u00ae 5 mg Tablets\n      (Reference formulation; Eli Lilly and Company, USA). Dosing periods were separated by a\n      washout period during fasted study.\n\n      Study Design:\n\n      Open-Label, Randomised, two Period, two treatment, Crossover, Single-Dose Bioequivalence\n      Study"
        }, 
        "brief_title": "Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Olanzapine Orally Disintegrating 5mg Tablets Under Fasting Condition", 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        The volunteers were included in the study based on the following criteria:\n\n          -  Sex: male.\n\n          -  Age: 18 - 45 years.\n\n          -  Volunteer with BMI of 18-27 (inclusive both) kg/m2 with minimum of 50 kg weight.\n\n          -  Healthy and willing to participate in the study.\n\n          -  Volunteer willing to adhere to the protocol requirements and to provide written\n             informed consent.\n\n          -  Non-smokers or smoker who smokes less than 10 cigarettes per day\n\n        Exclusion Criteria:\n\n        The volunteers were excluded from the study based on the following criteria:\n\n          -  Clinically relevant abnormalities in the results of the laboratory screening\n             evaluation.\n\n          -  Clinically significant abnormal ECG or Chest X-ray.\n\n          -  Systolic blood pressure less than 100 mm Hg or more than 140 mm Hg and diastolic\n             blood pressure less than 60 mm Hg or more than 90 mm Hg.\n\n          -  Pulse rate less than 50/minute or more than 100/minute. Oral temperature less than\n             95\u00b0P or more than 98.6\u00b0P.\n\n          -  Respiratory rate less than 12/minute or more than 20/minute\n\n          -  History of allergy to the test drug or any drug chemically similar to the drug under\n             investigation.\n\n          -  History of alcohol or drug abuse\n\n          -  Positive breath alcohol test\n\n          -  Recent history of kidney or liver dysfunction.\n\n          -  History of consumption of prescribed medication since last 14 days or OTC medication\n             since last 07 days before beginning of the study.\n\n          -  Volunteers suffering from any chronic illness such as arthritis, asthma etc.\n\n          -  History of heart failure.\n\n          -  HIV, HCV, HBsAg positive volunteers.\n\n          -  Opiate, tetra hydrocannabinol, amphetamine, barbiturates, benzodiazepines, Cocaine\n             positive volunteers based on urine test.\n\n          -  Volunteers suffering from any psychiatric (acute or chronic) illness requiring\n             medications.\n\n          -  Administration of any study drug in the period 0 to 3 months before entry to the\n             study.\n\n          -  History of significant blood loss due to any reason, including blood donation in the\n             past 3 months.\n\n          -  History of pre-existing bleeding disorder.\n\n          -  Existence of any surgical or medical condition, which, in the judgment of the chief\n             investigator and/or clinical investigator/physician, might interfere with the\n             absorption, distribution, metabolism or excretion of the drug or likely to compromise\n             the safety of volunteers.\n\n          -  Inability to communicate or co-operate due to language problem, poor mental\n             development or impaired cerebral function."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01996488", 
            "org_study_id": "PK-07-134"
        }, 
        "intervention": {
            "arm_group_label": "Torrent's Olanzapine Orally Disintegrating Tablets 5mg", 
            "intervention_name": "Olanzapine Orally Disintegrating Tablets 5mg", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Olanzapine"
        }, 
        "lastchanged_date": "November 21, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Village Bhat, Gandhinagar", 
                    "country": "India", 
                    "state": "Gujarat", 
                    "zip": "382428"
                }, 
                "name": "Bio Evaluation Centre, Torrent Pharmaceuticals Ltd."
            }
        }, 
        "location_countries": {
            "country": "India"
        }, 
        "official_title": "An Open Label, Randomised, 2-Period, 2-Treatment, 2-Sequence, Crossover, Single-Dose Bioequivalence Study of Olanzapine Orally Disintegrating 5mg Tablets (Test Formulation; Torrent Pharmaceuticals Ltd., India) Versus Zyprexa\u00ae Zydis\u00ae 5 mg Tablets (Reference Formulation; Eli Lilly and Company, USA) in Healthy Human Volunteers Under Fasting Condition.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "India: Drugs Controller General of India", 
                "India: Indian Council of Medical Research"
            ]
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "bioequivalence; 90% geometric confidence interval of the ratio of least-squares means of the test to reference product should be within 80.00% - 125.00% for AUC-unf, AUCo-t and Cmax.", 
            "measure": "bioequivalence based on Composite of Pharmacokinetics", 
            "safety_issue": "No", 
            "time_frame": "plasma samples were obtained from blood drawn at Pre-dose and 0.5, 1.00, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 5.50, 6.00, 6.50, 7.00, 8.00, 10.00, 12.00, 14.00, 18.00 and 24.00 hours after dose administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01996488"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Torrent Pharmaceuticals Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Torrent Pharmaceuticals Limited", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "N/A", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}